Moreover, despite the recent approval, the development of resistance to the KRAS G12C inhibitors has already been reported, limiting the therapeutic efficacy and clinical application of such drugs to treat KRAS-mutated cancers [47,48]. This evidence concerns the gene KRAS and cancer.